http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109852684-B
Outgoing Links
Predicate | Object |
---|---|
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00 |
filingDate | 2019-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2019-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2019-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-109852684-B |
titleOfInvention | Hsa_circ_0003764 is preparing the application in Asherman's syndrom diagnostic preparation as marker |
abstract | The invention discloses hsa_circ_0003764 as marker is preparing the application in Asherman's syndrom diagnostic preparation.Hsa_circ_0003764 expression is significant in Asherman's syndrom patient uterine's inner membrance scar tissue increases, and is resistant to the digestion of exoribonuclease R (RNase R), more more stable than linear rna.In vitro cell experiment shows that hsa_circ_0003764 can cause the fibrosis of inner membrance interstitial apoptosis and epithelial cell.Si-hsa_circ_0003764 has the function of anti-epithelium fibrosis.Therefore, hsa_circ_0003764 can be used as Asherman's syndrom diagnosis marker and apply in the reagent for preparing disease caused by the fibrosis of diagnostic factro palace.Hsa_circ_0003764 as therapy target preparation treatment because of fibrosis of uterus caused by disease drug in apply.The reagent of detection hsa_circ_0003764 is applied in the diagnostic reagent for preparing Asherman's syndrom. |
priorityDate | 2019-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 247.